CN102539758A - Application method of human lung adenocarcinoma protein marker Flotillin-1 - Google Patents
Application method of human lung adenocarcinoma protein marker Flotillin-1 Download PDFInfo
- Publication number
- CN102539758A CN102539758A CN2011104406966A CN201110440696A CN102539758A CN 102539758 A CN102539758 A CN 102539758A CN 2011104406966 A CN2011104406966 A CN 2011104406966A CN 201110440696 A CN201110440696 A CN 201110440696A CN 102539758 A CN102539758 A CN 102539758A
- Authority
- CN
- China
- Prior art keywords
- adenocarcinoma
- lung
- flotillin
- lung adenocarcinoma
- human lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention provides an application method of a human lung adenocarcinoma protein marker Flotillin-1 which is applicable to the preparation of preparations for the diagnosis, prediction, detection, or screening of lung adenocarcinoma; and is also applicable to the preparation of preparations for the diagnosis, prediction, detection, or screening of lung adenocarcinoma cell proliferation, lung adenocarcinoma lymph node metastasis, lung adenocarcinoma clinical staging, and lung adenocarcinoma patient recurrence. The invention provides scientific basis for the effective determination of lung adenocarcinoma canceration process.
Description
Technical field
The present invention relates to a kind of application process that is used as the plasmalemma protein Flotillin-1 of human lung adenocarcinoma mark.
Background technology
Lung cancer is modal malignant tumour, and its M & M has occupied first of the malignant tumour, the serious threat human health.As one type of lung cancer, adenocarcinoma of lung accounts for 20 ∽ 30% in all kinds of lung cancer.In recent years, the incidence of disease of human lung adenocarcinoma is progressively rising, and patient's mortality ratio is high, poor prognosis.Clinically, concealment of adenocarcinoma of lung morbidity does not generally have tangible clinical symptoms in early days, and the invasion and attack or the transfer of cancer cell have taken place when going to a doctor Most patients, and do not have the mark of effectively judging the adenocarcinoma of lung canceration.Therefore, seek the effective marker thing of adenocarcinoma of lung, accurately judge the clinical stages of adenocarcinoma of lung and the urgent task that prognosis becomes numerous medical investigators.
Summary of the invention
Flotillin-1 among the present invention is a kind of labelled protein of Lipid Rafts.People Flotillin-1 gene (Genebank accession number ID 10211) is positioned at chromosome 6p21.3 section, and total length 15kb is made up of 13 extrons and 12 intrones.Flotillins albumen is considered to belong to SPFH (stomatins, prohibitins, flotillins, HflK/C) protein family.People Flotillin-1 albumen is made up of 427 amino acid; (protein accession number O75955; Www.expasy.org) its wide expression in vivo; And high conservative, this is just pointing out it in different tissues and cell, bringing into play different effects, but its function definite in adenocarcinoma of lung is unclear.
Summary of the invention
The application process that the purpose of this invention is to provide a kind of human lung adenocarcinoma protein markers Flotillin-1; For judging that effectively adenocarcinoma of lung canceration process provides scientific basis.
A kind of human lung adenocarcinoma protein markers Flotillin-1 is used to prepare the preparation of diagnosis, prediction, detection or examination human lung adenocarcinoma; Kit especially for preparation diagnosis, prediction, detection or examination human lung adenocarcinoma.
A kind of human lung adenocarcinoma protein markers Flotillin-1 can also be used to prepare the preparation of diagnosis, prediction, detection or the diffusion of examination human lung adenocarcinoma cancer cell, adenocarcinoma of lung lymphatic metastasis, adenocarcinoma of lung clinical stages, adenocarcinoma of lung patient's recurrence; The kit that recurs especially for preparation diagnosis, prediction, detection or the diffusion of examination human lung adenocarcinoma cancer cell, adenocarcinoma of lung lymphatic metastasis, adenocarcinoma of lung clinical stages, adenocarcinoma of lung patient.
The invention provides a plasmalemma protein mark Flotillin-1 who is used to distinguish human lung adenocarcinoma tissue and cancer other normal lung tissue, no lymphatic metastasis pulmonary adenocarcinoma and the lymphatic metastasis pulmonary adenocarcinoma is arranged; Utilize this mark preparation to judge human lung adenocarcinoma, adenocarcinoma of lung diffusion, the preparation of adenocarcinoma of lung lymphatic metastasis, clinical stages, adenocarcinoma of lung patient's recurrence and prognosis.The present invention provides scientific basis for effectively judging human lung adenocarcinoma canceration process.
Description of drawings
Fig. 1 is that human lung adenocarcinoma is organized plasma membrane purity evaluation figure.Wherein 1-A is a transmission electron microscope collection of illustrative plates behind the plasma membrane purifying, and 1-B is that Western blotting detects plasma membrane purifying front and back Na
+/ K
+ATPase (plasma membrane marker protein) and Prohibitin (particulate body mark albumen) expression, 1-C are Na before and after the plasma membrane purifying
+/ K
+ATPase and Prohibitin expression histogram.WTL representes the total tissue lysate, and PM representes the plasma membrane behind the purifying.
Fig. 2 is twice iTRQA reagent mark, the peptide sequence of LC-MS/MS Analysis and Identification Flotillin-1 and quantitative ratio figure.Fig. 2-A is the other normal lung tissue of 114 and 116 a reagent mark cancers plasmalemma protein, 115 and 117 reagent mark pulmonary adenocarcinoma plasmalemma proteins, the peptide sequence of mass spectrum evaluation Flotillin-1 (VTGEVLDILR, m/z=680.4019, z=2) and scale map.Fig. 2-B is the other normal lung tissue of 115 and 117 a reagent mark cancers plasmalemma protein; 114 and 116 reagent mark pulmonary adenocarcinoma plasmalemma proteins; Mass spectrum is identified the peptide sequence LAEAEK00SQLIMQAEAEAASVR of Flotillin-1, and m/z=845.1227 is z=3) with quantitative ratio figure.These two sequences are a section in the Flotillin-1 protein sequence all, detects respectively during twice mass spectrophotometry to obtain, and combines bioinformatics to identify through mass spectrometric data and is Flotillin-1.
Fig. 3 is that Western blot detection Flotillin-1 expresses in human lung adenocarcinoma tissue and the other normal lung tissue of cancer.Fig. 3-A is that Western blot detection Flotillin-1 expresses in pulmonary adenocarcinoma and the other normal lung tissue of cancer, and (N representes the other normal tissues of human lung adenocarcinoma cancer, and T representes the human lung adenocarcinoma tissue; PNLT representes the other normal lung tissue of cancer, and AdC representes the human lung adenocarcinoma tissue; GAPDH albumen is as organizing confidential reference items; Fig. 3-B is Flotillin-1 expression histogram in human lung adenocarcinoma tissue and the other normal lung tissue of cancer.
Fig. 4 is that SABC detects Flotillin-1 in the other normal lung tissue of cancer, and no metastatic lymph node pulmonary adenocarcinoma is expressed with having in the lymphatic metastasis lung pulmonary adenocarcinoma.4-A is Flotillin-1 SABC figure in the other normal lung tissue of cancer, and 4-B is Flotillin-1 SABC figure in no metastatic lymph node pulmonary adenocarcinoma, and 4-C is Flotillin-1 SABC figure in lymphatic metastasis lung pulmonary adenocarcinoma is arranged.
Fig. 5 is the graph of a relation of expression and adenocarcinoma of lung recurrence and the patient's existence of Kaplan-Meier tracing analysis Flotillin-1.5-A is expression and the adenocarcinoma of lung recurrence Kaplan-Meier tracing analysis figure of Flotillin-1, and 5-B is expression and the adenocarcinoma of lung patient of the Flotillin-1 Kaplan-Meier tracing analysis figure that survives.Relapse-free Probability representes not have recurrence rate, and Overall Survival representes overall survival rate.
Embodiment
Below in conjunction with embodiment the present invention is elaborated, and can not limit the present invention.
The plasma membrane purifying: it is even broken that people's lung (gland cancer) is organized in Potter-Elvehjem Tissue Grinders, filtered through gauze, and remaining thick tissue adds HEPS liquid and in liquid nitrogen, grinds, and refilters, and centrifugal 10 minutes of merging filtrate 3200g goes deposition, and centrifugal 1 hour of 100000g gets and is precipitated as thick plasma membrane.Thick plasma membrane suspends with HEPS again, adds centrifugal 10 minutes of 6.4%Detran/PEG system mixing 750g again, gets the upper strata, and lower floor continues with centrifugal 10 minutes of new 6.4%Detran/PEG system mixing 750g.Merge the upper strata twice, at 1mM NaHCO
3In the solution 100000 centrifugal 1 hour, collecting precipitation carried out plasma membrane purity with Electronic Speculum and Westerb blot respectively and identifies.Fig. 1-A is the pollution that the plasma membrane of transmission electron microscope collection of illustrative plates demonstration this method extraction behind the plasma membrane purifying is not found other organelles such as particulate body; Plasma membrane marker protein Na behind Fig. 1-B and Fig. 1-C explanation plasma membrane purifying
+/ K
+The full lysis liquid enrichment of the expression ratio of ATPase 12 times, and the full cell pyrolysis liquid of expression ratio of the marker protein Prohibitin of particulate body has reduced 10 times.The method that this purifying people lung (gland cancer) tissue plasma membrane is described thus is effective, and the plasma membrane purity of purifying is higher.
ITRQA mark and mass spectrophotometry: this method has been carried out twice different iTRQA mark and mass spectrophotometry to two groups of samples.Mark for the first time; Behind the plasmalemma protein matter accurate quantification; Equal protein matter is used the other normal lung tissue of 114 and 116 reagent mark cancers plasma membrane peptide hydrolysis respectively behind the pancreatin enzymolysis; And 115 and 117 reagent mark pulmonary adenocarcinoma plasma membrane peptide hydrolysis carry out the LC-MS/MS mass spectrophotometry on Qstar XL LC-MS appearance.Fig. 2-A and Fig. 2-B are the mass spectrograms of twice mark before and after the Flotillin-1, from figure, can obtain Flotillin-1 and in pulmonary adenocarcinoma, express rising.Twice mass spectrometric data Treatment Analysis result (seeing table 1) also finds that Flotillin-1 expresses rising in pulmonary adenocarcinoma simultaneously.
The differential expression of table 1.iTRQA labeled analysis Flotillin-1 in adenocarcinoma of lung and the other normal tissues of cancer
The checking of embodiment 3 Western blottings
Be the difference of checking Flotillin-1 in human lung adenocarcinoma and the other normal tissues of cancer, we adopt Western blot to detect Flotillin-1 in 18 pairs of adenocarcinomas of lung and the other normal tissue expression level of pairing cancer.
Operating process is following:
1) collects 18 pairs of human lung adenocarcinomas and the other normal lung tissue of pairing cancer sample.
2) protein extracting: in liquid nitrogen, pulmonary adenocarcinoma and normal lung lung tissue are ground earlier, add indissoluble respectively and organize lysate (0.375mol/L Tris-HCl pH 8.8,1%SDS; 50m mmol/L DTT, 25% Glycerol, 1mM PMSF; 25 μ g/mL Aprotinin, 25 μ g/mL Leupeptin), cracking 1h on ice; Get supernatant behind 12000rpm, the 4 ℃ of centrifugal 30min and be the histocyte total protein, the Bradford method is measured protein concentration.
3) SDS-PAGE electrophoresis: 50 μ g total proteins carry out 10% polyacrylamide gel electrophoresis (SDS-PAGE) to be separated, on albumen electrotransfer to the nitrocellulose membrane (PVDF).
4) blotting membrane spends the night with 5% skim milk room temperature sealing 2h or 4 ℃ of sealings.
5) (the TBS-T damping fluid is washed film 3 times to the specific antibody 1 of blotting membrane and Flotillin-1 then for the purchase of abcam company, ab50671) (concentration 0.55 μ g/mL) incubated at room 2h or 4 ℃ of incubated overnight, each 10min.
6) with SA (the anti-IgG of rabbit) the incubated at room 1h of film and HR mark, the TBS-T damping fluid is washed film 3 times, each 10min.
7) luminous, development of ECL reagent and photographic fixing.With GAPDH is interior reference.The experiment triplicate
Fig. 3 is the expression of 5 pairs of typical pulmonary adenocarcinoma and the other Flotillin-1 of normal lung tissue of pairing cancer.3 figure results show that Flotillin-1 expresses rising in pulmonary adenocarcinoma.
Embodiment 4
The clinical meaning that immunohistochemical analysis Flotillin-1 expresses in pulmonary adenocarcinoma
We with Flotillin-1 specific antibody 2 (abcam company buys, and ab41927) unites to step new S-P SABC kit (Fujian steps new company) and form our diagnostic kit, and it is following that immunohistochemical staining is pressed concise and to the point step:
1) the paraffin organization chip section is with 100% xylene dewaxing 2 times, and each 20-40min is to dewaxing is clean fully;
2) with after 100%, 95%, 90%, the 75% gradient alcohol aquation, with PBS liquid (PH6.0) flushing 3 times, each 3min;
3) antigen retrieval: the section that will handle well places the section frame, puts into the beaker that contains the 1000ml citrate buffer, and electric furnace directly is heated to boiling, continues to boil 15min with little fire;
4) beaker is left burning things which may cause a fire disaster, naturally cool to room temperature, distilled water flushing twice, twice of PBS liquid flushing;
5) every section adds a peroxidase blocking solution (stepping novel agent box reagent A), hatches 10min under the room temperature.PBS flushing three times, each 3min;
6) remove PBS liquid, add a normal non-immune serum (stepping novel agent box reagent B), hatch 10min under the room temperature;
7) remove serum deprivation, (abcam company buys, and ab41927) (12 μ g/mL) 4 ℃ spends the night to add Flotillin-1 specific antibody 2 respectively.Replace an anti-negative contrast with PBS;
8) the PBS flushing is three times, each 3min.Remove PBS liquid, every section adds two anti-(stepping novel agent box reagent C) of a drip mark, hatches 10min under the room temperature.PBS flushing three times, each 3min;
9) remove PBS liquid, every section adds a streptomysin antibiotin-superoxide enzyme solutions (stepping novel agent box reagent D), hatches 10min under the room temperature.PBS flushing three times, each 3min;
10) remove PBS liquid, every section adds the DAB solution of two fresh configurations, and microscopically is observed 3-10min;
11) tap water flushing, haematoxylin is redyed, and indigo plant is returned in the tap water flushing;
12) gradient alcohol dehydration is dry, and xylene is transparent, the neutral gum sealing.
We comprise that to the paraffin-embedded tissue specimen that files the other normal lung tissue of 42 routine cancers, the 46 no lymphatic metastasis pulmonary adenocarcinoma of example and 62 examples have the lymphatic metastasis pulmonary adenocarcinoma to analyze with immunohistochemical staining.The dyeing standards of grading are following: at least 10 high power lens visuals field of picked at random (* 200), count 1000 cell number at least, with integral method result of calculation.Promptly unite score according to the staining power and the positive cell ratio of every section.Tinctorial strength: colourless 0 minute; Light yellow 1 minute; Pale brown look 2 minutes; Brown 3 minutes.Painted cells ratio: non-coloring branch;＜30% is 1 minute; 30%～60% is 2 minutes;＞60% is 3 minutes.Two kinds of scoring additions of tinctorial strength and painted cells ratio, the person expressed for low in 0～2 minute, and 3～4 fens persons are medium expression, and 5～6 fens persons are high expressed.Data statistics divides adopts SPSS13.0 software to carry out.The result is following:
1: immunohistochemical analysis Flotillin-1 is in cancer other normal lung tissue, no lymphatic metastasis pulmonary adenocarcinoma and the expression of lymphatic metastasis pulmonary adenocarcinoma is arranged.Fig. 4-A is the typical picture that Flotillin-1 expresses in the other normal lung tissue of cancer, is low express (feminine gender); 4-B is the typical picture that Flotillin-1 expresses in no lymphatic metastasis pulmonary adenocarcinoma, for moderate is expressed; 4-C is the typical picture that Flotillin-1 expresses in the lymphatic metastasis pulmonary adenocarcinoma is arranged, and is high expressed (strong positive).Table 1 result shows that Flotillin-1 is in cancer other normal lung tissue, no lymphatic metastasis pulmonary adenocarcinoma with have the expression of lymphatic metastasis pulmonary adenocarcinoma to exist between any two to have statistical significance difference on (p＜0.05).Flotillin-1 expresses major part and is low express (negative rate 88%) in the other normal lung tissue of cancer; And Flotillin-1 most of positive expression (positive rate 67%) in the pulmonary adenocarcinoma tissue; And than the obvious height of expressing in the no lymphatic metastasis pulmonary adenocarcinoma, there is significant difference (p＜0.05) in Flotillin-1 in the lymphatic metastasis pulmonary adenocarcinoma is arranged.
The other normal lung tissue of table 2:Flotillin-1 cancer, no lymphatic metastasis adenocarcinoma of lung and differential expression in the lymphatic metastasis pulmonary adenocarcinoma is arranged
A representes other normal tissues of cancer and no lymphatic metastasis pulmonary adenocarcinoma statistical comparisons between the two,
B representes not have the lymphatic metastasis pulmonary adenocarcinoma and lymphatic metastasis pulmonary adenocarcinoma statistical comparisons is between the two arranged;
*P＜0.05.
The relation of 2:Flotillin-1 expression and adenocarcinoma of lung clinical pathological factors in pulmonary adenocarcinoma
Utilize single factor variance (Kruskal-Wallis test) to analyze Flotillin-1 clinical pathological factors variable of expression and adenocarcinoma of lung patient in pulmonary adenocarcinoma and comprise age (age), sex (gender), tumour differentiation (Differentiation), tumour big or small (pT stage), lymphatic metastasis state (pN stage) and the relation between clinical stages (Clinical stage).Statistics is found (seeing table 3): Flotillin-1 expression in pulmonary adenocarcinoma relevant with lymphatic metastasis and clinical stages (p＜0.05), and lymphatic metastasis takes place the adenocarcinoma of lung patient of Flotillin-1 high expressed more easily, has later clinical stages.And Flotillin-1 expression and age, sex, tumour differentiation and tumour size in pulmonary adenocarcinoma all do not have significant correlation property.
The table expression of 3.Flotillin-1 in adenocarcinoma of lung and the relation of clinical pathologic characteristic
The relation of 3:Flotillin-1 expression and adenocarcinoma of lung patient recurrence
Adopt the relation of Kaplan-Meier method and regretional analysis Flotillin-1 expression and adenocarcinoma of lung patient recurrence; Kaplan-Meier tracing analysis result shows; Along with Flotillin-1 expression in the pulmonary adenocarcinoma increases; Its no recurrence rate (Relapse-free probability) obviously reduces (sees that Fig. 5-A), promptly recurrence rate obviously raises.Single argument Cox regretional analysis result shows (seeing the left hurdle of table 4): the adenocarcinoma of lung lymphatic metastasis is arranged, the expression of clinical stages and Flotillin-1 (p＜0.05) with the relevant factor of adenocarcinoma of lung recurrence; The multivariate regression analysis result shows (seeing the left hurdle of table 5): lymphatic metastasis, the high expressed of clinical stages and Flotillin-1 are the risk factors (p＜0.05) of adenocarcinoma of lung recurrence.
Table 4: the correlation factor of univariate analysis adenocarcinoma of lung patient recurrence and prognosis
Overall p＜0.01.
The relation of 4:Flotillin-1 expression and adenocarcinoma of lung patients'prognosis
Adopt the relation of Kaplan-Meier method and regretional analysis Flotillin-1 expression and adenocarcinoma of lung patients'prognosis; Kaplan-Meier tracing analysis result shows: along with Flotillin-1 expression in the pulmonary adenocarcinoma increases, adenocarcinoma of lung patient's survival rate obviously descends and (sees Fig. 5-B).Single argument Cox regretional analysis result shows (seeing the right hurdle of table 4): the adenocarcinoma of lung lymphatic metastasis, and the expression of clinical stages and Flotillin-1 (p＜0.05) is relevant with the adenocarcinoma of lung prognosis of patients; The multivariate regression analysis result shows (seeing the right hurdle of table 5): lymphatic metastasis, clinical stages,, high expressed later and Flotillin-1 was adenocarcinoma of lung independent prognostic factor (p＜0.05).
The correlation factor of table 5. multivariable analysis adenocarcinoma of lung patient recurrence and prognosis
Overall p＜0.05.
Claims (4)
1. the application process of a human lung adenocarcinoma protein markers Flotillin-1 is characterized in that, described mark is used to prepare the preparation of diagnosis, prediction, detection or examination human lung adenocarcinoma.
2. application process according to claim 1 is characterized in that, described mark is used to prepare the kit of diagnosis, prediction, detection or examination human lung adenocarcinoma.
3. the application process of a human lung adenocarcinoma protein markers Flotillin-1; It is characterized in that described mark is used to prepare the preparation of diagnosis, prediction, detection or the diffusion of examination human lung adenocarcinoma cancer cell, adenocarcinoma of lung lymphatic metastasis, adenocarcinoma of lung clinical stages, adenocarcinoma of lung patient's recurrence.
4. application process according to claim 3; It is characterized in that described mark is used to prepare the kit of diagnosis, prediction, detection or the diffusion of examination human lung adenocarcinoma cancer cell, adenocarcinoma of lung lymphatic metastasis, adenocarcinoma of lung clinical stages, adenocarcinoma of lung patient's recurrence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110440696.6A CN102539758B (en) | 2011-12-26 | 2011-12-26 | Application method of human lung adenocarcinoma protein marker Flotillin-1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110440696.6A CN102539758B (en) | 2011-12-26 | 2011-12-26 | Application method of human lung adenocarcinoma protein marker Flotillin-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102539758A true CN102539758A (en) | 2012-07-04 |
| CN102539758B CN102539758B (en) | 2014-03-19 |
Family
ID=46347156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110440696.6A Active CN102539758B (en) | 2011-12-26 | 2011-12-26 | Application method of human lung adenocarcinoma protein marker Flotillin-1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102539758B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104789689A (en) * | 2015-05-13 | 2015-07-22 | 北京泱深生物信息技术有限公司 | CLEC9A gene serving as lung adenocarcinoma diagnosis and treatment target |
| CN106243211A (en) * | 2015-06-04 | 2016-12-21 | 欧蒙医学诊断技术有限公司 | The diagnosis of neurological autoimmune disease |
| CN106282347A (en) * | 2016-08-17 | 2017-01-04 | 中南大学 | HoxC11 as biomarker preparation adenocarcinoma of lung pre-diagnostic reagent in application |
| CN107102141A (en) * | 2016-02-23 | 2017-08-29 | 中国科学院生物物理研究所 | Molecular marked compound CD71 and Endometrial Carcinomas diagnosis, the application by stages and in prognosis |
| CN109385478A (en) * | 2018-12-20 | 2019-02-26 | 首都医科大学附属北京朝阳医院 | The genetic marker for detecting 19-GCS is preparing the application in the product for diagnosing early stage adenocarcinoma of lung prognosis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003048305A2 (en) * | 2001-11-13 | 2003-06-12 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
| US20060211025A1 (en) * | 2001-06-10 | 2006-09-21 | Irm Llc | Molecular signatures of commonly fatal carcinomas |
| CN101448938A (en) * | 2006-03-28 | 2009-06-03 | 佐藤升志 | Novel tumor antigen peptides |
| KR20090132264A (en) * | 2008-06-20 | 2009-12-30 | 덕성여자대학교 산학협력단 | Anticancer composition |
| WO2010140694A1 (en) * | 2009-06-04 | 2010-12-09 | 大日本住友製薬株式会社 | Method for screening of inhibitor using factor capable of enhancing production of amyloid-beta peptide, and inhibitor obtained by same |
-
2011
- 2011-12-26 CN CN201110440696.6A patent/CN102539758B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211025A1 (en) * | 2001-06-10 | 2006-09-21 | Irm Llc | Molecular signatures of commonly fatal carcinomas |
| WO2003048305A2 (en) * | 2001-11-13 | 2003-06-12 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
| CN101448938A (en) * | 2006-03-28 | 2009-06-03 | 佐藤升志 | Novel tumor antigen peptides |
| KR20090132264A (en) * | 2008-06-20 | 2009-12-30 | 덕성여자대학교 산학협력단 | Anticancer composition |
| WO2010140694A1 (en) * | 2009-06-04 | 2010-12-09 | 大日本住友製薬株式会社 | Method for screening of inhibitor using factor capable of enhancing production of amyloid-beta peptide, and inhibitor obtained by same |
Non-Patent Citations (5)
| Title |
|---|
| FRANCESCA RAIMONDO, ET AL: "Caveolin-1 and Flotillin-1 differential expression in clinical samples of renal cell carcinoma", 《THE OPEN PROTEOMICS JOURNAL》, no. 1, 31 December 2008 (2008-12-31) * |
| SIMON STAUBACH AND FRANZ-GEORG HANISCH: "Lipid rafts: signaling and sorting platforms of cells and their roles in cancer", 《EXPERT REVIEW OF PROTEOMICS》, vol. 8, no. 2, 30 April 2011 (2011-04-30) * |
| 刘永生等: "细胞型朊蛋白PrP~C与浮舰蛋白flotillin功能的研究进展", 《中国农业大学学报》, vol. 14, no. 03, 15 June 2009 (2009-06-15), pages 12 - 16 * |
| 詹显全等: "人肺腺癌细胞A-549和正常细胞HBE的蛋白质组差异分析", 《生物化学与生物物理学报》, vol. 34, no. 01, 15 January 2002 (2002-01-15), pages 50 - 56 * |
| 赵峰等: "脂筏标记蛋白flotillin-1的研究进展", 《中国兽医科学》, vol. 41, no. 08, 20 August 2011 (2011-08-20), pages 865 - 869 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104789689A (en) * | 2015-05-13 | 2015-07-22 | 北京泱深生物信息技术有限公司 | CLEC9A gene serving as lung adenocarcinoma diagnosis and treatment target |
| CN104789689B (en) * | 2015-05-13 | 2018-10-02 | 北京泱深生物信息技术有限公司 | CLEC9A genes as adenocarcinoma of lung diagnosis and treatment target |
| CN106243211A (en) * | 2015-06-04 | 2016-12-21 | 欧蒙医学诊断技术有限公司 | The diagnosis of neurological autoimmune disease |
| CN106243211B (en) * | 2015-06-04 | 2022-11-08 | 欧蒙医学实验诊断股份公司 | Diagnosis of neuroautoimmune diseases |
| CN107102141A (en) * | 2016-02-23 | 2017-08-29 | 中国科学院生物物理研究所 | Molecular marked compound CD71 and Endometrial Carcinomas diagnosis, the application by stages and in prognosis |
| CN106282347A (en) * | 2016-08-17 | 2017-01-04 | 中南大学 | HoxC11 as biomarker preparation adenocarcinoma of lung pre-diagnostic reagent in application |
| CN109385478A (en) * | 2018-12-20 | 2019-02-26 | 首都医科大学附属北京朝阳医院 | The genetic marker for detecting 19-GCS is preparing the application in the product for diagnosing early stage adenocarcinoma of lung prognosis |
| CN109385478B (en) * | 2018-12-20 | 2021-08-03 | 首都医科大学附属北京朝阳医院 | Application of gene marker for detecting 19-GCS in preparation of product for diagnosing early lung adenocarcinoma prognosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102539758B (en) | 2014-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akazaki et al. | Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii | |
| CN102539758B (en) | Application method of human lung adenocarcinoma protein marker Flotillin-1 | |
| CN109557311B (en) | Colorectal cancer diagnosis marker, colorectal cancer detection product and application thereof | |
| Hu et al. | Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1 | |
| CN102687011A (en) | Cancer biomarker and the use thereof | |
| CN109266740A (en) | For pulmonary cancer diagnosis or the marker and diagnostic reagent of prognosis | |
| Shi et al. | Mex3a expression and survival analysis of bladder urothelial carcinoma | |
| Xu et al. | Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer | |
| Qi et al. | Proteomic profiling of N‐linked glycoproteins identifies C on A‐binding procathepsin D as a novel serum biomarker for hepatocellular carcinoma | |
| Wu et al. | Spalt-like transcription factor 4 as a potential diagnostic and prognostic marker of colorectal cancer | |
| Wang et al. | Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer | |
| Tsui et al. | Comparisons of voided urine cytology, nuclear matrix protein‐22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China | |
| CN112229997B (en) | Prognostic diagnosis marker Claudin23 for ovarian cancer and application thereof | |
| Ferro et al. | A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy | |
| CN112229998A (en) | Prognostic diagnosis marker Claudin22 for ovarian cancer and application thereof | |
| CN102735831A (en) | Uses of truncated retinoic acid induced protein 16 (tRAI16) as hepatocellular carcinoma marker | |
| CN112229999B (en) | Prognostic diagnosis marker Claudin21 for ovarian cancer and application thereof | |
| Taniguchi et al. | MicroRNA‐20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma | |
| CN114015773B (en) | Application of systemic inflammatory response index in prognosis evaluation of gastrointestinal diffuse large B cell lymphoma | |
| Shi et al. | Assessment of serum tumor markers for predicting ocular metastasis in lung adenocarcinoma: a retrospective study | |
| Ge et al. | High expression of ZNF692 impairs overall survival in patients with colorectal cancer-analysis of immunohistochemical staining and bioinformatics data | |
| Yu et al. | Effect of renal function and hemodialysis on the serum tumor markers in patients with chronic kidney disease | |
| Zeng et al. | Differences in serum cytokine levels distinguish between clinically non‐invasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study | |
| Abas et al. | Diagnostic and prognostic role of serum Ki-67 and HE4 levels in Egyptian breast cancer patients | |
| Dakubo et al. | Cancer biomarkers in interstitial fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIANGYA HOSPITAL, CENTRAL-SOUTH CHINA UNIV. Free format text: FORMER OWNER: CENTRAL SOUTH UNIVERSITY Effective date: 20140814 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410083 CHANGSHA, HUNAN PROVINCE TO: 410008 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140814 Address after: 410008 Hunan Changsha Xiangya road 87, Xiangya Hospital of Central South University Patentee after: Xiangya Hospital, Central-South China Univ. Address before: Yuelu District City, Hunan province 410083 Changsha Lushan Road No. 932 Patentee before: Central South University |